MX353713B - Composiciones de administracion dermica y metodos. - Google Patents

Composiciones de administracion dermica y metodos.

Info

Publication number
MX353713B
MX353713B MX2014005294A MX2014005294A MX353713B MX 353713 B MX353713 B MX 353713B MX 2014005294 A MX2014005294 A MX 2014005294A MX 2014005294 A MX2014005294 A MX 2014005294A MX 353713 B MX353713 B MX 353713B
Authority
MX
Mexico
Prior art keywords
progestin
methods
estrogen
disclosed
delivery compositions
Prior art date
Application number
MX2014005294A
Other languages
English (en)
Other versions
MX2014005294A (es
Inventor
Agis Kydonieus
Charles G Arnold
Thomas M Rossi
Alfred F Altomari
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of MX2014005294A publication Critical patent/MX2014005294A/es
Publication of MX353713B publication Critical patent/MX353713B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulga una composición para administración transdérmica de una progestina para una terapia de hormona de progestina. También se divulga un dispositivo de administración transdérmica que comprende la composición. Para la terapia de hormona únicamente de progestina, la composición contiene un anti-oxidante y no contiene un estrógeno. Para la terapia que implica una progestina y un estrógeno, la composición contiene la progestina, el estrógeno y un anti-oxidante adicional. También se describen métodos de mejora de la estabilidad de las composiciones que contienen progestina que comprenden agentes oxidativos. Los métodos comprenden incluir uno o más anti-oxidantes en las composiciones.
MX2014005294A 2011-11-04 2012-11-02 Composiciones de administracion dermica y metodos. MX353713B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555546P 2011-11-04 2011-11-04
US201261645778P 2012-05-11 2012-05-11
PCT/US2012/063314 WO2013067346A1 (en) 2011-11-04 2012-11-02 Dermal delivery compositions and methods

Publications (2)

Publication Number Publication Date
MX2014005294A MX2014005294A (es) 2014-09-22
MX353713B true MX353713B (es) 2018-01-24

Family

ID=47278507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005294A MX353713B (es) 2011-11-04 2012-11-02 Composiciones de administracion dermica y metodos.

Country Status (16)

Country Link
US (3) US9364487B2 (es)
EP (1) EP2773333B1 (es)
JP (1) JP6316749B2 (es)
KR (1) KR20140088199A (es)
CN (1) CN103957899A (es)
AU (1) AU2012332254B2 (es)
BR (1) BR112014010670A2 (es)
CA (1) CA2854164C (es)
EA (1) EA026664B1 (es)
ES (1) ES2762460T3 (es)
HK (2) HK1200317A1 (es)
IL (1) IL232258A0 (es)
IN (1) IN2014DN03247A (es)
MX (1) MX353713B (es)
WO (1) WO2013067346A1 (es)
ZA (1) ZA201402988B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
GB2521632B (en) * 2013-12-23 2020-12-16 Linscott Goode Steven Vermin control compositions
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20200330371A1 (en) * 2017-10-30 2020-10-22 Teikoku Seiyaku Co., Ltd. Transdermally administrable preparation
RU2020117569A (ru) * 2017-10-30 2021-12-01 Какен Фармасьютикал Ко., Лтд. Препарат для местного применения для лечения трихофитического онихомикоза
BR112021005253A2 (pt) * 2018-09-19 2021-06-15 Isp Investments Llc composição de polímero estável a peróxido e processo para sua preparação e aplicações da mesma
CN113455506A (zh) * 2021-06-29 2021-10-01 无锡宏霸医疗科技有限公司 一种适用于日化产品的水相除臭去味剂及其制备方法
CN114259498B (zh) * 2021-12-02 2023-04-28 南通联亚药业股份有限公司 一种包含去氧孕烯和炔雌醇的药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
FR2739031B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
EP1197212A4 (en) * 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
PT1242012E (pt) * 1999-11-24 2010-03-31 Agile Therapeutics Inc Sistema e processo melhorado de libertação transdérmica de contraceptivo
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
EP1127567B1 (de) * 2000-02-17 2010-09-01 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
JP4422430B2 (ja) * 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
WO2006036899A2 (en) * 2004-09-27 2006-04-06 Corium International, Inc. Transdermal systems for the delivery of estrogens and progestins
AU2006236564B2 (en) * 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2006128057A2 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
DE102006050558B4 (de) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
EP2086550A2 (en) * 2006-11-29 2009-08-12 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
JP5603235B2 (ja) 2007-07-10 2014-10-08 アージャイル セラピューティクス， インコーポレイテッド イン・サイチュシールを有する経皮送達デバイス
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
US20100292660A1 (en) 2007-07-10 2010-11-18 Agis Kydonieus Dermal delivery device with ultrasonic weld
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
US9198920B2 (en) * 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones

Also Published As

Publication number Publication date
JP2014532719A (ja) 2014-12-08
WO2013067346A1 (en) 2013-05-10
CA2854164A1 (en) 2013-05-10
US20130116222A1 (en) 2013-05-09
US20160250226A1 (en) 2016-09-01
IL232258A0 (en) 2014-06-30
AU2012332254B2 (en) 2017-06-22
US20180325916A1 (en) 2018-11-15
ES2762460T3 (es) 2020-05-25
JP6316749B2 (ja) 2018-04-25
CA2854164C (en) 2021-04-13
EP2773333B1 (en) 2019-10-02
US9364487B2 (en) 2016-06-14
MX2014005294A (es) 2014-09-22
EA201400543A1 (ru) 2014-09-30
AU2012332254A1 (en) 2014-05-15
KR20140088199A (ko) 2014-07-09
ZA201402988B (en) 2015-11-25
HK1200317A1 (en) 2015-08-07
CN103957899A (zh) 2014-07-30
EA026664B1 (ru) 2017-05-31
NZ624117A (en) 2016-02-26
HK1201152A1 (en) 2015-08-28
EP2773333A1 (en) 2014-09-10
BR112014010670A2 (pt) 2017-05-09
IN2014DN03247A (es) 2015-05-22

Similar Documents

Publication Publication Date Title
MX353713B (es) Composiciones de administracion dermica y metodos.
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
MX365818B (es) Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2014015897A (es) Terapias de reemplazo hormonal transdermicas.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MX2013008528A (es) Composicion de androgeno para tratar una afeccion oftalmica.
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MX367596B (es) Tratamientos transdermicos de sustitucion hormonal.
TN2015000394A1 (en) Pharmaceutical compositions comprising everolimus
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
PH12015501187A1 (en) Method for synchronizing time of insemination in gilts
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX2014008693A (es) Administracion transdermica de hormonas.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
PL397785A1 (pl) Kompozycja i preparat zawierajace tioproline i ergotioneine, zastosowanie tioproliny i ergotioneiny oraz sposób ochrony skóry przed procesem starzenia zewnatrzpochodnego
RU2010139486A (ru) Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA74103U (ru) Способ лечения переднего эндогенного увеита, ассоциированного со спондилоартритами
WO2012031999A3 (en) Low-dose transdermal patches with high drug release

Legal Events

Date Code Title Description
FG Grant or registration